These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 17241925)
1. Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients. Sun JY; Dagis A; Gaidulis L; Miller MM; Rodriguez R; Parker P; Nademanee A; Falk P; Rosenthal J; Forman SJ; Senitzer D Biol Blood Marrow Transplant; 2007 Feb; 13(2):197-205. PubMed ID: 17241925 [TBL] [Abstract][Full Text] [Related]
2. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709 [TBL] [Abstract][Full Text] [Related]
3. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E; Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053 [TBL] [Abstract][Full Text] [Related]
5. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Kröger N; Binder T; Zabelina T; Wolschke C; Schieder H; Renges H; Ayuk F; Dahlke J; Eiermann T; Zander A Transplantation; 2006 Oct; 82(8):1024-30. PubMed ID: 17060849 [TBL] [Abstract][Full Text] [Related]
6. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Sobecks RM; Ball EJ; Maciejewski JP; Rybicki LA; Brown S; Kalaycio M; Pohlman B; Andresen S; Theil KS; Dean R; Bolwell BJ Bone Marrow Transplant; 2007 Apr; 39(7):417-24. PubMed ID: 17310134 [TBL] [Abstract][Full Text] [Related]
7. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Clausen J; Kircher B; Auberger J; Schumacher P; Ulmer H; Hetzenauer G; Wolf D; Gastl G; Nachbaur D Biol Blood Marrow Transplant; 2010 Feb; 16(2):273-80. PubMed ID: 19857587 [TBL] [Abstract][Full Text] [Related]
8. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C; Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295 [TBL] [Abstract][Full Text] [Related]
9. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation. Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012 [TBL] [Abstract][Full Text] [Related]
10. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Morishima Y; Yabe T; Matsuo K; Kashiwase K; Inoko H; Saji H; Yamamoto K; Maruya E; Akatsuka Y; Onizuka M; Sakamaki H; Sao H; Ogawa S; Kato S; Juji T; Sasazuki T; Kodera Y; Biol Blood Marrow Transplant; 2007 Mar; 13(3):315-28. PubMed ID: 17317585 [TBL] [Abstract][Full Text] [Related]
11. Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation. Yabe T; Matsuo K; Hirayasu K; Kashiwase K; Kawamura-Ishii S; Tanaka H; Ogawa A; Takanashi M; Satake M; Nakajima K; Tokunaga K; Inoko H; Saji H; Ogawa S; Juji T; Sasazuki T; Kodera Y; Morishima Y; Biol Blood Marrow Transplant; 2008 Jan; 14(1):75-87. PubMed ID: 18158964 [TBL] [Abstract][Full Text] [Related]
12. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population. Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784 [TBL] [Abstract][Full Text] [Related]
13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]